CircVMP1 promotes glycolysis and disease progression by upregulating HKDC1 in colorectal cancer.
HKDC1
circRNA
colorectal cancer
glycolysis
hsa_circ_0006508
Journal
Environmental toxicology
ISSN: 1522-7278
Titre abrégé: Environ Toxicol
Pays: United States
ID NLM: 100885357
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
revised:
16
10
2023
received:
21
03
2023
accepted:
14
11
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
Circular RNAs (circRNAs) have been reported to play important roles in cancers. Here, we characterized circVMP1 (hsa_circ_0006508), an important circRNA which promoted glycolysis and disease progression in colorectal cancer (CRC). In this study, we aimed to explore the mechanism by which circVMP1 regulated tumor glycolysis and its related pathways in promoting CRC cell proliferation and metastasis. The expression level of circVMP1 in CRC tissues and adjacent normal tissues was detected using quantitative PCR. In vitro and in vivo functional experiments were used to evaluate the effects of circVMP1 in the regulation of CRC cell proliferation and migration. Mitochondrial stress tests and glycolysis stress tests were conducted to detect the effect of circVMP1 on oxidative phosphorylation and glycolysis. Dual-luciferase reporter and RNA immunoprecipitation assays were used to evaluate the interaction between circVMP1, miR-3167, and HKDC1. We demonstrated that the level of circVMP1 was significantly upregulated in CRC tissues compared with normal tissues. In HCT116 and SW480 cells, overexpression of circVMP1 promoted proliferation, metastasis, and glycolysis. In vivo analysis indicated that circVMP1 accelerated the proliferation of xenograft tumors. As for the mechanism, overexpression of circVMP1 increased the levels of hexokinase domain component 1 (HKDC1) through competitive binding with miR-3167. Our study reported that circVMP1 was one of the tumor driver genes that promoted CRC malignant progression and glycolysis by upregulating HKDC1. CircVMP1/miR-3167/HKDC1 was a signaling axis that might be a target for CRC therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Circular RNAs (circRNAs) have been reported to play important roles in cancers. Here, we characterized circVMP1 (hsa_circ_0006508), an important circRNA which promoted glycolysis and disease progression in colorectal cancer (CRC). In this study, we aimed to explore the mechanism by which circVMP1 regulated tumor glycolysis and its related pathways in promoting CRC cell proliferation and metastasis.
METHODS
METHODS
The expression level of circVMP1 in CRC tissues and adjacent normal tissues was detected using quantitative PCR. In vitro and in vivo functional experiments were used to evaluate the effects of circVMP1 in the regulation of CRC cell proliferation and migration. Mitochondrial stress tests and glycolysis stress tests were conducted to detect the effect of circVMP1 on oxidative phosphorylation and glycolysis. Dual-luciferase reporter and RNA immunoprecipitation assays were used to evaluate the interaction between circVMP1, miR-3167, and HKDC1.
RESULTS
RESULTS
We demonstrated that the level of circVMP1 was significantly upregulated in CRC tissues compared with normal tissues. In HCT116 and SW480 cells, overexpression of circVMP1 promoted proliferation, metastasis, and glycolysis. In vivo analysis indicated that circVMP1 accelerated the proliferation of xenograft tumors. As for the mechanism, overexpression of circVMP1 increased the levels of hexokinase domain component 1 (HKDC1) through competitive binding with miR-3167.
CONCLUSION
CONCLUSIONS
Our study reported that circVMP1 was one of the tumor driver genes that promoted CRC malignant progression and glycolysis by upregulating HKDC1. CircVMP1/miR-3167/HKDC1 was a signaling axis that might be a target for CRC therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 8180235
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490-1502. doi:10.1016/s0140-6736(13)61649-9
Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17(4):205-211. doi:10.1038/nrm.2015.32
Zhang P, Zhang XO, Jiang T, et al. Comprehensive identification of alternative back-splicing in human tissue transcriptomes. Nucleic Acids Res. 2020;48(4):1779-1789. doi:10.1093/nar/gkaa005
Rybak-Wolf A, Stottmeister C, Glažar P, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58(5):870-885. doi:10.1016/j.molcel.2015.03.027
Li B, Zhu L, Lu C, et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021;12(1):295. doi:10.1038/s41467-020-20527-z
Guo R, Cui X, Li X, et al. CircMAN1A2 is upregulated by Helicobacter pylori and promotes development of gastric cancer. Cell Death Dis. 2022;13(4):409. doi:10.1038/s41419-022-04811-y
Chen Z, He L, Zhao L, et al. circREEP3 drives colorectal cancer progression via activation of FKBP10 transcription and restriction of antitumor immunity. Adv Sci. 2022;9(13):e2105160. doi:10.1002/advs.202105160
Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675-691. doi:10.1038/s41576-019-0158-7
Xu H, Liu Y, Cheng P, et al. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis. J Exp Clin Cancer Res. 2020;39(1):283. doi:10.1186/s13046-020-01799-1
Liu CX, Chen LL. Circular RNAs: characterization, cellular roles, and applications. Cell. 2022;185(13):2390. doi:10.1016/j.cell.2022.06.001
Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 2016;16(10):635-649. doi:10.1038/nrc.2016.77
Boese AC, Kang S. Mitochondrial metabolism-mediated redox regulation in cancer progression. Redox Biol. 2021;42:101870. doi:10.1016/j.redox.2021.101870
Zheng M, Wu C, Yang K, et al. Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis. Pharmacol Res. 2021;164:105367. doi:10.1016/j.phrs.2020.105367
Khan MW, Ding X, Cotler SJ, Clarke M, Layden BT. Studies on the tissue localization of HKDC1, a putative novel fifth hexokinase, in humans. J Histochem Cytochem. 2018;66(5):385-392. doi:10.1369/0022155418756849
Guo J, Ye F, Xie W, et al. The HOXC-AS2/miR-876-5p/HKDC1 axis regulates endometrial cancer progression in a high glucose-related tumor microenvironment. Cancer Sci. 2022;113(7):2297-2310. doi:10.1111/cas.15384
Wang X, Shi B, Zhao Y, et al. HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway. Cancer Cell Int. 2020;20:450. doi:10.1186/s12935-020-01539-7
Wang MQ, Chen YR, Xu HW, et al. HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer. Cancer Sci. 2022;114:1365-1377. doi:10.1111/cas.15692
Fuhr L, El-Athman R, Scrima R, et al. The circadian clock regulates metabolic phenotype rewiring via HKDC1 and modulates tumor progression and drug response in colorectal cancer. EBioMedicine. 2018;33:105-121. doi:10.1016/j.ebiom.2018.07.002
Li XN, Wang ZJ, Ye CX, Zhao BC, Li ZL, Yang Y. RNA sequencing reveals the expression profiles of circRNA and indicates that circDDX17 acts as a tumor suppressor in colorectal cancer. J Exp Clin Cancer Res. 2018;37(1):325. doi:10.1186/s13046-018-1006-x
Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452-464. doi:10.1038/s41568-018-0005-8
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-234. doi:10.1038/nrd1984
Mirzaei H, Hamblin MR. Regulation of glycolysis by non-coding RNAs in cancer: switching on the Warburg effect. Mol Ther Oncolytics. 2020;19:218-239. doi:10.1016/j.omto.2020.10.003
Chen B, Huang S. Circular RNA: An emerging non-coding RNA as a regulator and biomarker in cancer. Cancer Lett. 2018;418:41-50. doi:10.1016/j.canlet.2018.01.011
Long F, Lin Z, Li L, et al. Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer. Mol Cancer. 2021;20(1):26. doi:10.1186/s12943-021-01318-6
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891-899. doi:10.1038/nrc1478
Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol. 2008;18(5):330-337. doi:10.1016/j.semcancer.2008.03.011
Khan MW, Terry AR, Priyadarshini M, et al. The hexokinase “HKDC1” interaction with the mitochondria is essential for liver cancer progression. Cell Death Dis. 2022;13(7):660. doi:10.1038/s41419-022-04999-z
Sartore-Bianchi A, Loupakis F, Argilés G, Prager GW. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Ann Oncol. 2016;27(8):1456-1466. doi:10.1093/annonc/mdw191
De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist Updates: Rev Comment Antimicrob Anticancer Chemother. 2015;20:39-70. doi:10.1016/j.drup.2015.05.003
Lai X, Li Q, Wu F, et al. Epithelial-mesenchymal transition and metabolic switching in cancer: lessons from somatic cell reprogramming. Front Cell Dev Biol. 2020;8:760. doi:10.3389/fcell.2020.00760
Ramesh V, Brabletz T, Ceppi P. Targeting EMT in cancer with repurposed metabolic inhibitors. Trends Cancer. 2020;6(11):942-950. doi:10.1016/j.trecan.2020.06.005
Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49(3):361-374. doi:10.1016/j.devcel.2019.04.010
Blaha CS, Ramakrishnan G, Jeon SM, et al. A non-catalytic scaffolding activity of hexokinase 2 contributes to EMT and metastasis. Nat Commun. 2022;13(1):899. doi:10.1038/s41467-022-28440-3
Marcucci F, Rumio C. Glycolysis-induced drug resistance in tumors-a response to danger signals? Neoplasia. 2021;23(2):234-245. doi:10.1016/j.neo.2020.12.009
Ng L, Li X, Wan TM, et al. Investigation of miRNA dysregulation and association with immune cell profile during malignant transformation of colorectal cells. Eur J Surg Oncol. 2022;48(1):245-252. doi:10.1016/j.ejso.2021.09.016
Slattery ML, Herrick JS, Mullany LE, et al. Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis. Mod Pathol. 2016;29(8):915-927. doi:10.1038/modpathol.2016.73
Qu W, Wei X, Zhang H, Hou J. FOXD1-AS1 promotes malignant behaviours of prostate cancer cells via the miR-3167/YWHAZ axis. Andrologia. 2022;54(1):e14263. doi:10.1111/and.14263